Glioblastoma in neurofibromatosis 1 patients without IDH1, BRAF V600E, and TERT promoter mutations

Gutmann DH, Parada LF, Silva AJ et al (2012) Neurofibromatosis type 1: modeling CNS dysfunction. J Neurosci 32:14087–14093

Neurofibromatosis (1988) Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 45:575–578

Rasmussen SA, Friedman JM (2000) NF1 gene and neurofibromatosis 1. Am J Epidemiol 151:33–40

Gutmann DH, Rasmussen SA, Wolkenstein P et al (2002) Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). Neurology 59:759–761

Rodriguez FJ, Perry A, Gutmann DH et al (2008) Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J Neuropathol Exp Neurol 67:240–249

Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110

Alexandrescu S, Korshunov A, Lai SH et al (2016) Epithelioid glioblastomas and anaplastic epithelioid pleomorphic xanthoastrocytomas-same entity or first cousins? Brain pathology 26:215–223

Kleinschmidt-DeMasters BK, Aisner DL, Birks DK et al (2013) Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol 37:685–698

Singh G, Das KK, Sharma P et al (2015) Cerebral gliosarcoma: analysis of 16 patients and review of literature. Asian J Neurosurg 10:195–202

Sonoda Y, Yokosawa M, Saito R et al (2010) O (6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. Int J Clin Oncol. https://doi.org/10.1007/s10147-010-0065-6

Shibahara I, Sonoda Y, Kanamori M et al (2012) IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas. Int J Clin Oncol 17:551–561

Shibahara I, Sonoda Y, Saito R et al (2013) The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence. Neuro Oncol 15:1151–1159

Fransen K, Klintenas M, Osterstrom A et al (2004) Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 25:527–533

Sonoda Y, Kumabe T, Nakamura T et al (2009) Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 100:1996–1998

Eckel-Passow JE, Lachance DH, Molinaro AM et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508

Weller M, Felsberg J, Hartmann C et al (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 27:5743–5750

Miyata S, Sugimoto T, Kodama T et al (2005) Adenoid glioblastoma arising in a patient with neurofibromatosis type-1. Pathol Int 55:348–352

Kroh H, Matyja E, Marchel A et al (2004) Heavily lipidized, calcified giant cell glioblastoma in an 8-year-old patient, associated with neurofibromatosis type 1 (NF1): report of a case with long-term survival. Clin Neuropathol 23:286–291

Jeong TS, Yee GT (2014) Glioblastoma in a patient with neurofibromatosis type 1: a case report and review of the literature. Brain Tumor Res Treat 2:36–38

Taraszewska A, Bogucki J, Powala A et al (2013) Giant cell glioblastoma with unique bilateral cerebellopontine angle localization considered as extraaxial tumor growth in a patient with neurofibromatosis Type 1. Clin Neuropathol 32:58–65

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2016) WHO classification of tumours of the central nervous system, 4th edn. IARC Press, Lyon

Laycock-van Spyk S, Thomas N, Cooper DN et al (2011) Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis. Hum Genom 5:623–690

Jones DT, Kocialkowski S, Liu L et al (2008) Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68:8673–8677

Adeleye AO, Okolo CA, Akang EE et al (2012) Cerebral pleomorphic xanthoastrocytoma associated with NF1: an updated review with a rare atypical case from Africa. Neurosurg Rev 35:313–319 (discussion 319)

Takei H, Rouah E, Bhattacharjee MB (2015) Cerebellar pleomorphic xanthoastrocytoma in a patient with neurofibromatosis type 1: a case report and literature review. Int J Clin Exp Pathol 8:7570–7574

Saikali S, Le Strat A, Heckly A et al (2005) Multicentric pleomorphic xanthoastrocytoma in a patient with neurofibromatosis type 1. Case report and review of the literature. J Neurosurg 102:376–381

Naidich MJ, Walker MT, Gottardi-Littell NR et al (2004) Cerebellar pleomorphic xanthoastrocytoma in a patient with neurofibromatosis type 1. Neuroradiology 46:825–829

Hariharan S, Donahue JE, Garre C et al (2006) Clinicopathologic and genetic analysis of siblings with NF1 and adult-onset gliomas. J Neurol Sci 247:105–108

Rutledge WC, Kong J, Gao J et al (2013) Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. Clin Cancer Res 19:4951–4960

Ratner N, Miller SJ (2015) A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer 15:290–301

Singh AD, Iftinca M, Easaw JC (2013) Lipidized glioblastoma: pathological and molecular characteristics. Neuropathology 33:87–92

Gupta K, Kalra I, Salunke P et al (2011) Lipidized glioblastoma: a rare differentiation pattern. Neuropathology 31:93–97

Kanamori M, Suzuki H, Takei H et al (2016) Malignant transformation of diffuse astrocytoma to glioblastoma associated with newly developed BRAF V600E mutation. Brain Tumor Pathol 33:50–56

Arita H, Narita Y, Fukushima S et al (2013) Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 126:267–276

Matsumura N, Nakajima N, Yamazaki T et al (2017) Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma. Neuropathology 37:58–63

Huttner AJ, Kieran MW, Yao X et al (2010) Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1. Pediatr Blood Cancer 54:890–896

Dahiya S, Emnett RJ, Haydon DH et al (2014) BRAF-V600E mutation in pediatric and adult glioblastoma. Neuro Oncol 16:318–319

Vizcaino MA, Shah S, Eberhart CG et al (2015) Clinicopathologic implications of NF1 gene alterations in diffuse gliomas. Hum Pathol 46:1323–1330

Philpott C, Tovell H, Frayling IM et al (2017) The NF1 somatic mutational landscape in sporadic human cancers. Hum Genom 11:13

Bikowska-Opalach B, Szlufik S, Grajkowska W et al (2014) Pilocytic astrocytoma: a review of genetic and molecular factors, diagnostic and prognostic markers. Histol Histopathol 29:1235–1248